Sunshine Biopharma Inc. (SBFM)
SBFM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/0001683168-26-002644-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SBFM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001402328 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | CO |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36.3M |
| Net income | -$6.0M |
| Operating income | -$6.2M |
| Net margin | -16.5% |
| Operating margin | -17.2% |
| Revenue growth | +4.1% |
| Cash | $9.1M |
| Total assets | $30.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $14.6M cash; operating cash flow -$1.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 823,772 (2026-11-12); 4,905,945 a year earlier; 25,678,290 three years earlier. 1y figure adjusted for splits (1-for-200 overall); 3y figure adjusted for splits (1-for-400000 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 4; latest 1-for-20 on 2026-10-26 | Source 2026-10-26 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-07-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | M&K CPAS, PLLC, The Woodlands, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-09-30 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.4M | -$1.2M | -$1.4M | $14.6M | No debt tags | $35.4M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $9.3M | -$1.6M | -$918K | $13.7M | No debt tags | $35.3M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $8.1M | -$1.2M | -$2.1M | $6.9M | No debt tags | $35.5M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $8.6M | -$2.1M | -$1.6M | $9.1M | $0 | $36.3M | 10-K 2026-04-03 |
| Q3 2025 2025-09-30 | $9.4M | -$884K | -$747K | $9.3M | No debt tags | $37.3M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $9.4M | -$1.8M | -$1.3M | $10.3M | No debt tags | $36.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $8.9M | -$1.2M | -$1.7M | $8.1M | No debt tags | $36.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $9.6M | -$2.2M | -$3.4M | $9.7M | $0 | $34.9M | 10-K 2026-04-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2026-10-09 |
| Latest annual report FORM 10-K FOR DEC 2025 | 10-K | 2026-04-03 |
| Latest quarterly / interim FORM 10-Q FOR SEP 2026 | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-14 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-11-13 |
Source: SEC EDGAR submissions feed, 432 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -42.8% |
| 3 months | -88.8% |
| Year to date | -98.9% |
| 1 year | -99.2% |
| From 52-week high | -99.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier